Meeting
2014 ASCO Annual Meeting
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
Authors
Mairead Geraldine McNamara
Princess Margaret Cancer Centre, Toronto, ON, Canada
Mairead Geraldine McNamara , Lisa W Le , Anne M Horgan , Alex Aspinall , Kelly W Burak , Neesha C. Dhani , Eric Xueyu Chen , Mehrdad Sinaei , Glen Lo , Tae Kyoung Kim , Patrik Rogalla , Oliver F. Bathe , Jennifer J. Knox
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT 01334112
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4092)
DOI
10.1200/jco.2014.32.15_suppl.4092
Abstract #
4092
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon
Poster
2018 ASCO Annual Meeting
Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
First Author: Imane H. El Dika
Poster
2017 ASCO Annual Meeting
A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2017 Gastrointestinal Cancers Symposium
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
First Author: Andrew X. Zhu